Recent Achievements in Simulated Moving Bed (SMB) Technology. Part I. by Šunjić, Vitomir et al.
Recent Achievements in Simulated Moving
Bed (SMB) Technology. Part I.
V. Šunjiæ,a D. Franiæ,a D. Kontrec,b and M. Rojeb
a Chirallica Ltd., Bijenièka cesta 54, 10002 Zagreb, Croatia
b Ruðer Boškoviæ Institute, Bijenièka cesta 54, 10002 Zagreb, Croatia
Simulated moving bed (SMB) technology is over half a century known in continuous chroma-
tographic separation of binary mixtures. Invented and developed in the petrochemical and sugar
industries, it was recognized by organic chemists in the pharmaceutical industry as a powerful
tool in separation of racemic mixtures. Over the years, it was developed into a standard labora-
tory, then pilot-plant and finally large-scale method for production of chiral compounds in the
optically pure form. Final products of this technology are enantiopure drugs, other biologically ac-
tive compounds and their intermediates. In Part I of this review, the basic principles and selected
examples of recent SMB technology applications are presented.
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1. Introduction
In view of the fact that most research chemists in Croatia,
both in academy and industry, are engaged in research
projects aimed at the synthesis of compounds with poten-
tial biological activity, many of them chiral in the racemic
form, this review is expected to promote their interest in the
application of enantioseparation in general, and SMB tech-
nology in particular.
In 1961, Broughton and Gerhold from Universal Oil Prod-
ucts (UOP) introduced the concept of simulated moving
bed (SMB).1 SMB technology was first applied by UOP for
large scale separations in the petrochemical industry. For
nearly half a century SMB was used for separation of xylene
from other C8 aromatics, and separation of n-paraffins from
branched and cyclic hydrocarbons. After successful appli-
cation in separation of glucose from fructose, two structur-
ally isomeric aldohexoses, this method was applied in sepa-
ration of enantiomers in racemic mixtures. The main differ-
ence between chromatographic conditions in separation of
structurally similar compounds like structural isomers and
diastereomers on one side, and enantiomers on the other,
lies in the fact that the former can be separated on achiral
stationary phases, typically on silica gel, whereas the latter
require chiral stationary phases (CSPs) in the chromato-
graphic columns to achieve enantioseparation.
For separations in the sugar industry, the columns of the
SMB unit are typically filled with cheap ion-exchange resins
with a large particle diameter (200–500 m). Twelve to
twenty-four columns are commonly used with a bed length
of 1 m. For chiral applications, the situation is quite diffe-
rent. The CSPs are expensive materials, the cost being
mainly related to the chemical complexity of the chiral
selector (CS). Optimization of the process usually leads to
the reduction of the packing particle size and selection of
the optimal number of the columns in order to minimize
the separation cost. Furthermore, for chiral applications,
the consumption, usually single organic solvent or mixture
thereof, typically stays between 100 and 1000 L kg–1 of
feed (racemic material). Of course, recycling is greatly simp-
lified if a one-component eluent is used in SMB.
The SMB process, originally developed to replace conven-
tional, less effective techniques such as distillation or batch
chromatography, has found widespread application and
more than 130 units have been licensed by UOP.2,3 The
first examples of the SMB for enantiomer separations ap-
peared in the early 1990s.4–6 The interest in the develop-
ment of the SMB technology grew once its potential to
perform chiral separations was realized.7,8 Within five years
of the first chiral separation demonstrations, UCB Pharma,
in 1997, installed a multi-ton SMB unit for large-scale
manufacturing.9 Further in 2002, Lundbeck’s single enan-
tiomer drug Lexapro became the first US Food and Drug
Administration’s (FDA) approved drug to be manufactured
using SMB technology.10 Although it is hard to assess the full
reach of the technology, due to confidentiality issues, sev-
eral key active pharmaceutical ingredients (APIs) are manu-
factured using this technology and several installations are
being operated around the world.11,12
Preparing this review, we found over 1700 papers and pat-
ents, related to the development and application of SMB
technology, cited in the electronic databases. Approx. 1100
citations appear after the year 2000, and in the last five
years nearly 500 citations on SMB were found. Mostly, the
results on the progress of SMB technology in the last decade
were therefore covered by this review, since previous
achievements were covered by the chapters in the former
monographs13–19 and review articles.20–23 Emphasis is given
to the recent successful application in enantioseparation of
racemates of definite commercial interest, either intermedi-
ates or target compounds with specific biological activity.
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2. Discontinuous and continuous
chiral chromatography
2.1. Discontinuous chromatographic
separation of enantiomers
Chromatographic separation on various CSPs is discussed in
detail in the recent monographs and reviews.24–28 We have
published an author-review related to our research on
novel CSPs,29 and informative overviews in this techno-
logy-oriented journal.30,31 For easier following of the dis-
cussion in this section, only two aspects of chiral chro-
matography are briefly commented; the main types of chiral
selectors (CS) nowadays in common use, and elementary
thermodynamics of chromatographic enantioseparation.
Two important elements distinguish the two main types of
CS; molar mass and type of binding to silica. According to
mol. mass, CS are either derived from chiral polymers, usu-
ally from polysaccharides or proteins, or they are small chi-
ral molecules, often designed on purpose for separation of
specific racemate, and named “brush-type” or “Pirkle
type”, according to the inventor of such CSPs.32 Poly-
saccharide-based chiral selectors represent over 90 % of the
market, and in even a higher percentage if the number of
reported separation of racemates were considered. Repeat-
edly cited in this review, Fig. 1,33 are four of them, called
“the golden four”, which practically cover this market – two
of them are based on cellulose (Chiralcel), and the other
two on amylose (Chiralpak). The financial dimension of the
world market of chiral technologies was cca. $5 billion in
1999, and is expected to more than triple in 2009.34
According to the type of binding, CS can be either non-
-covalently adsorbed, as is usual for polymer-based CS, or
covalently bound to the activated surface of silica gel. How-
ever, there is still a need for new covalent binding modes of
both, polymer-based and small-molecule, or “brush-type”
CSPs. Fig. 2 presents the structures of five selected, com-
mercial “brush-type” selectors.
Thermodynamics of enantioseparation is based on the sim-
ple model of equilibrium between free and bound analyte,
i.e. two enantiomers to be separated, Fig. 3.
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F i g. 1 – Four most important polysaccharide-based chiral se-
lectors (“the golden four”)33
S l i k a 1 – Èetiri najvaÞnija kiralna selektora (“èetiri zlatna”) zas-
novana na polisaharidima33
F i g. 2 – Five selected commercial brush-type CSPs33
S l i k a 2 – Pet odabranih komercijalnih CSP-a èetkolikog tipa33
It is important to note that  is an experimentally easily
available parameter from kS/kR and KS/KR values. This pa-
rameter is usually used as comparison for efficacy of enan-
tiosepartion, whereas kS and kR values are similar or same
variables as the Henry constants HA and HB. These values,
along with binding constants and retention times, are the
key parameters for design of the SMB process, see section
2.4.
2.2. Simulated moving bed chromatography
Unlike other unit operations for separation, such as distilla-
tion, membrane permeation, or extraction, the SMB is not a
steady process but a steady periodic process. This means
that SMB is not operated under stead-state conditions, but
under cyclic steady-state conditions, also known as steady
periodic conditions.35,36 While the batch or elution chro-
matography mode has found the largest number of applica-
tions up to now, SMB chromatography as a steady periodic
process is gaining more attention due to its advantages in
terms of productivity, and eluent or desorbent consump-
tion. This concept is based on true moving bed chromatog-
raphy (TMB), represented schematically in Fig 4a. TMB
envisages countercurrent movement of the solid and liquid,
a concept difficult to reproduce in practice. In contrast, in
the SMB variant the adsorbent is distributed over a number
of fixed columns, 4–24 in standard equipment.
Eluent and feed streams enter the process continuously. A
counter-current solid stream is nearly reproduced by shift-
ing the inlet ports periodically in the direction of the inter-
nal recycle flow as shown in Fig. 4b, thus the solid stream is
“simulated”. This leads to the desired separation of the feed
components that can be withdrawn at the extract and raffi-
nate ports, which are shifted in the same manner as the in-
lets.37
In other words, conventional fixed bed chromatographic
columns can be used, and the inlet and outlet ports to the
unit are switched periodically in the direction of the fluid
flow to simulate, in a discontinuous manner, the continu-
ous countercurrent movement of the solid phase, Fig. 5.
Continuous movement is simulated better when the four
SMB sections consist of a large number of fixed bed col-
umns, 12 in Fig. 5, and the port switch occurs at high fre-
quency.
Design methods have been developed for robust operation
and scale-up, using data obtained from analytical experi-
ments. In the last few years, rapid developments have been
made in the areas of design, improved process schemes,
optimization and robust control. This review addresses
these developments, as well as both the fundamentals of
the SMB science and technology, and some practical issues
concerning the operation of SMB units.
Design and optimization of operating conditions for SMB
are computer-based processes, which use experimental
data from classic chromatography as the first input, and
simulate SMB conditions by specific programs, based on
separation theories of different sophistication degree. In
other words, SMB is based on the standard principles of
chromatography, but uses specific chromatographic set-ups
composed of a given number of chromatographic columns.
In comparison with preparative HPLC, chromatographic
separations using SMB units show several distinct advan-
tages, especially lower solvent consumption, lower require-
ment for CSP, and, of course, continuity.
Application and function of SMB cannot be understood,
however, without some basic knowledge of the theory, i.e.
of the guidelines and mathematic formalism for designing
and optimizing the results of classic chromatographic sepa-
ration. SMB units are complex systems, whose operations
require the choice of several parameters, e.g. flow rates in
the sections (columns), the periods between switching inlet
and outlet ports (valves), and the composition of the feed
(solvent plus racemate).
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F i g. 3 – Model of chromatographic enantioseparation and thermodynamics that describes the process
S l i k a 3 – Model kromatografske enantioseparacije i termodinamika koja opisuje proces
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F i g. 4 – Schematic presentation of: (a) four-section true moving bed (TMB) and (b) simulated moving bed (SMB) units separating a race-
mic mixture (R, S). The arrows in the TMB scheme indicate the direction of the species fluxes in each section of the unit working under com-
plete separation conditions.
S l i k a 4 – Shematski prikaz: (a) èetiri sekcije pravog pokretnog leÞaja (TMB) i (b) jedinice simuliranog pokretnog leÞaja koje razdvajaju
racemiènu smjesu (R, S). Strelice u shemi TMB oznaèavaju smjer toka pojedinih faza u svakoj sekciji postrojenja kada radi u uvjetima potpu-
nog odjeljivanja.
F i g. 5 – Principle of the simulated moving bed process with 12 columns
S l i k a 5 – Princip procesa simulirajuæeg pokretnog leÞaja (SMB) s 12 kolona
In the SMB model, the transport of a solute i along the axial
coordinate z of a chromatographic column in section j of
the SMB unit can be described by the following material
balance:
(1)
where ci,j and ni,j are the concentrations of the solute in the
fluid and solid phases respectively, e is the void fraction of
the column, and DL,i,j is the axial dispersion coefficient,
which to a good approximation may be linearly dependent
on the fluid velocity. The interstitial fluid velocity in section
j, vj, is related to the volumetric flow rate, Qj as vj = Q j/(A e),
where A denotes the cross sectional area of the column.
This equation is coupled to the mass balance in the solid
phase:
(2)
where ki,j is the mass transfer coefficient which is usually
weakly dependent on the fluid velocity, while n*i,j is the
solid phase concentration in equilibrium with the fluid
phase, which is given by a proper adsorption isotherm:
(3)
For the classical SMB process, these node balances relate
the internal flow rates Qj, (j = 1, …, 4) to the external flow
rates QD, QE, QF, QR, that denote the flow rates of the de-
sorbent, eluent, extract, feed and the raffinate streams, re-
spectively:
Q1 = Q4 + QD (4a)
Q2 = Q1 – QE (4b)
Q3 = Q2 + QF (4c)
Q4 = Q3 – QR (4d)
Similarly, component node balances can be written as:
(5a)
(5b)
(5c)
(5d)
where the superscripts “in” and “out” refer to the inlet and
outlet streams, respectively. Equations (5a)–(5d) along with
suitable initial and boundary conditions can be solved nu-
merically to obtain the transient behaviour of the SMB unit.
In addition, the switching mechanism is explicitly imple-
mented by assuming that the internal concentration profiles
are conserved within each physical column when the inlet
and outlet ports are switched (every t* time units). The
transport of solutes in chromatographic columns can lead to
shock fronts, and hence it is important to use high resolu-
tion schemes to solve the set of algebraic-partial differential
equations described above.38,39 Importantly, it is possible
to obtain pure components at the exit ports of the unit by
ensuring that the concentration fronts approaching the out-
let ports are pure. This is a characteristic feature of the SMB
that enhances its performance, compared to elution chro-
matography, especially when using columns that have low
efficiency.
2.3. Triangle theory of linear adsorption isotherms
The triangle theory allows an easy graphical description of
the internal flow-rates and the switch time, both of which
determine the flow-rate ratios yj in SMB unit. Flow-ratios
are defined by the eq. (6):
(j = 1 – 4)
(6)
where Qj (for j = 1 – 4) are the volumetric flow rates in sec-
tions 1–4 of the SMB, e* is the overall void volume, i.e. void
fractions of the columns. This parameter influences separa-
tion in small columns much more than for the large col-
umns. Parameter t* defines the switch time and V the single
column volume.
These isotherm parameters allow definition of the regions
in an “operating parameter plane” in the triangle presented
in Fig. 6. In this plane, the linear adsorption behaviour is re-
flected in the span of the flow-rate ratios y2 and y3, in the
central sections of the SMB unit. In this triangle, various ar-
eas can be distinguished. A triangular region describes an
area where the flow-rates in sections 2 and 3 of the SMB
lead to complete separation. This triangle is determined
through adsorption isotherms, the concentrations of the
two species to be separated, and the two Henry constants
HA and HB of the two enantiomers. Detailed explanation of
these parameters is given in the literature.40
The triangle diagram on “the y2, y3 plane” in Fig. 6 needs a
brief comment. It represents the operating point (w or q; .),
resulting from the internal flow-rates and the switch times.
Various areas in this plane describe different separation re-
gimes in terms of purity of the outlet streams. These points
are calculated according to equation (6).41 It is important to
note two regions above the central triangle; in the region on
the right, only the extract stream with more retained com-
pound is pure, while region on the left is where only the
raffinate stream with less adsorbed compound is pure.
This approach paves the way for rapid scale-up based on
the Henry constants HA and HB of the two enantiomers,
which can be easily measured analytically. The constraints
given by equations (7a–7d) define a region in the four di-
mensional space represented enclosed by the coordinates
yj, (j = 1, …, 4), that ensures the complete separation of the
binary mixture along with complete regeneration of both
the stationary and mobile phases.
HA  y1 (7a)
HB < y2 < HA (7b)
HB  y3 < HA (7c)
y4  HB (7d)
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The projection of these separation regions on the (y2, y3)
and (y1, y4) planes, as shown in Fig. 6a and 6b is worth con-
sidering. The constraints, given by eqs. (7b) and (7c), de-
limit a triangular region in the upper half of the (y2, y3)
plane, which corresponds to operating conditions that will
result in incomplete separation. Other regions can also be
identified on the (y2, y3) plane as indicated in the figure.
Similarly, the constraints given by equations (7a) and (7d),
delimit a rectangular region in the upper half of the (y1, y4)
plane that corresponds to the combination of y1 and y4 val-
ues that will result in a complete separation, provided the
constraints on y2 and y3 are satisfied. These diagrams show
that by proper choice of yj values, different separation per-
formances can be realized. This representation not only
gives explicit design equations, but also provides a method-
ology to rationalize the operation of the SMB process in
terms of yj values. Owing to the triangular nature of the re-
gion denoting the complete separation on the (y2, y3)
plane, this method of designing SMB has been termed as
the “triangle theory”.42,43 In spite of their applicability,
equations a and 7b are not necessarily followed by the ma-
jor part of industrial applications where operational condi-
tions are developed for concentrated mixtures because
they are in the nonlinear regime. Nonlinear conditions de-
sign is recently developed by the same authors.44,45
2.4. Design of the SMB process
Due to the cyclic steady state nature of the SMB process
and the rather complex dynamics of such a multi-column
chromatographic process, the detailed models presented in
the previous section are suitable for SMB simulations and
SMB optimization, but are not convenient as a basis to de-
velop criteria for SMB process design. Over the last twenty
years, the use of the equilibrium theory of linear and
nonlinear chromatography extended to multi-column pro-
cesses has been proven an extraordinarily useful tool for
process design. The triangle theory for linear adsorption iso-
therms proved particularly useful in deriving the design and
operating criteria for the complete separation of a binary
mixture of A (more retained solute), and B in a non-retained
solvent. To this aim, the design criteria for the SMB consider
the model of a chromatographic column within the frame
of the equilibrium theory, where axial dispersion is ne-
glected and local equilibrium between the fluid and the
solid phase is assumed, i.e. mass transfer resistances are
considered negligible. Under these assumptions, eq. (8) can
be recast as:
(8)
Provided the isotherm relationship, initial and boundary
conditions are available, it is possible to work towards the
solution of these equations analytically using the method of
characteristics.46,47 Let us assume that the adsorption iso-
therm is linear, i.e.:
(9)
where Hi is the Henry constant, and HA > HB. Under these
conditions, eq. (8) for R and S is decoupled and can be
solved easily for each species. The retention time of a sol-
ute, tRi,j, injected at the inlet of an SMB column located in
section j at time t = 0 is therefore:
(10)
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F i g. 6 – Complete separation region and SMB operating regimes on (a) (y2, y3) plane and (b) (y1, y4) plane for the binary separation of
species A and B, with linear adsorption isotherm
S l i k a 6 – Regije potpunog odjeljivanja i radni reÞim SMB-a na (a) (y2, y3)-ravnini i (b) (y1, y4)-ravnini za razdvajanje binarne smjese A i
B, uz linearne adsorpcijske izoterme
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The criteria for achieving complete separation of the binary
mixture in the linear case can be derived by considering the
specific role of the different sections in the SMB unit, Fig. 5.
Sections 2 and 3 perform the separation and hence it is
worth considering them first. The operation of section 3
should be designed in such a way that the switch time
should be larger than the retention time of component S in
section 3, and smaller than that of R. This will ensure that
component S reaches the raffinate port, whereas compo-
nent R does not contaminate it. In a similar fashion, section
2 should be designed in such away that the switch time
should be larger than the retention time of component S in
section 2, and smaller than that of R. This will ensure that S
is completely removed from the column and does not pol-
lute the extract after the next port switch, whereas R is still
present and can be collected in the extract. The role of sec-
tion 1 is to ensure that component R is completely re-
moved, or eluted before the next switch, so that stationary
phase is completely regenerated. Finally, the role of section
4 is to ensure that the fluid phase leaving is pure, i.e. solvent
free of component S.
2.5. Operational aspects of SMB technology
Before discussing some exciting examples of SMB separa-
tion of important chiral compounds, here are indicated
some key practical aspects of this technology. Nowadays,
SMB is the choice technology for industrial separation of
larger quantities of racemates, motivated by the following
benefits:
– easy scale up of the separation process
– short times required for implementation of production
process under good manufacturing practice (GMP) require-
ments
– reduced production costs
– broad productivity range, typically between 0.2 and 3 kg
kg–1 d–1 CSP.
Figure 7a shows the lab-scale SMB equipment at Chirallica
Ltd, which capacity can be extended from 1 g to 100 g d–1
of separated pure enantiomer. This equipment can adopt
columns from di = 4 mm to 16 mm, which have an approx.
filling capacity between 3–30 g of CSP. Figure 7b shows the
analytical and semi-preparative columns filled at Chirallica
Ltd, with CSPs produced and tested in this spin-off com-
pany.
The following are key practical steps in the development of
SMB technology;
– screening of CSPs by standard HPLC methods
– determination of the most effective couple CSP/eluent
system
– determination of loading capacity and adsorption iso-
therms for the most effective system
– identification of the system with highest productivity and
lowest solvent consumption.
3. Recent examples of industrial
application of SMB technology
SMB technology is best presented by examples of its suc-
cessful application in enantioseparation of racemates of
either structurally interesting or commercially important
compounds. This section should inform the reader about
the versatility of the method. Part II of this review presents
some inventive solutions related to SMB capacity to be inte-
grated in other (related) technological processes, such as
crystallization operating or enzyme catalyzed reactions.
The characteristic operative, technological parameters are
given for any presented separation, in order to illustrate the
vast spectrum of conditions developed for separations on
multigram to multi-kilo scales of important pharmaceutical
products. Many of them are high-volume drugs on the
world market, as presented in Part II of this review.
3.1. Separation of nonsteroidal antifinflamatorics
This section presents the examples of industrially devel-
oped processes for SMB separation of the representative
profenes, -arylpropionic acid derivatives, a group of anti-
inflmatory drugs with multibillion-dollar value on the world
market. For this group of drugs, it is well established that
S-enantiomers possess significantly better therapeutic in-
dex.48,49
S-Ketoprofen (1), 2-(3-benzoil)phenylpropionic acid. Race-
mic ketoprofen (Ketofen®) belongs to the well-known
group of non-steroidal anti-inflammatory agents.
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F i g. 7 – (a) Simulated moving bed system (Knauer SMB Pro-
duction System C9812) at Chirallica Ltd. (b) Analytical and prepa-
rative columns filled with original Chirallica CSPs.
S l i k a 7 – (a) Sustav simulirajuæeg pokretnog leÞaja u Chirallica
d. o. o. (b) Analitièke i preparativne kolone napunjene originalnim
kiralnim stacionarnim fazama (CSP) iz Chirallica d. o. o.
Recent study on the preparative chromatographic separa-
tion of ketoprofen enantiomers evaluated the choice of mo-
bile phase composition and measurement of competitive
adsorption isotherms.50 Best separation conditions were
obtained with amylose-based chiral stationary phase (Chi-
ralpak AD). Three mobile phase compositions were stud-
ied: the usual 20 % ethanol/80 % hexane mixture, and two
pure mobile phases: methanol and ethanol. The results ob-
tained show that, for preparative separations, pure ethanol
is a better mobile phase than the usual 20 % ethanol/80 %
n-hexane mixture; it allows higher solubility of the race-
mate, lower retention times, and also a higher selectivity at
high enantiomer concentrations.
It is interesting to mention, however, that Ketoprofen was
never introduced into therapy in the optically pure S-form,
since it was observed that specific group of enzymes, called
racemazes, converts in vivo S into R-enantiomer.51
S-Flurbiprofen (2), 2-(3-fluoro-4-phenyl)phenylpropionic
acid. SMB separation of racemic Flurbiprofen (Ansaid) is
specifically claimed among other separations of racemic
carboxylic acids.52
Large-scale separation is achieved using binary solvent mix-
ture consisting of low-boiling hydrocarbons and tert-bu-
tanol, and Chiralpak AD (20 m) as the most effective CSP.
The analysis determined that the enantiomeric purity of -
R-enantiomer in the extract was 99 %, and enantiomeric
purity of S-enantiomer in the raffinate was 98 %.
S-Ibuprofen (3), 2-(4-isobutyl)phenylpropionic acid. Ibu-
profen racemate (Advil) was separated in a SMB system
with 4 columns packed with TBB gels.53
TBB is a protein present in the mixture of TB proteins in
buckwheat (Fagopyrum), an annual melliferous crop grown
in many countries worldwide.54 Retention times of R- and
S-enantiomers of ibuprofen were measured in batch chro-
matographic experiments with hexane/TBME/AcOH mixed
solvent. Isotherm parameters of SMB were calculated from
the batch chromatographic data, and operation flow pa-
rameters obtained from y2 and y3 plane of Morbidelli and
coworkers.47
Loxoprofen (4), 2-(4-(cyclopentanon-2-yl)-methyl)phenyl-
propionic acid.
Since Loxoprofen racemate (Loxonin) has four enantiomers
owing to its two chiral centers, gaining a pure enantiomer is
impossible with only one step. To apply enrichment of
Loxoprofen using SMB, the extract and raffinate should be
separated as a binary mixture.
The enrichment of Loxoprofen (1S,2S)-enantiomer was
completed by 6-columns SMB chromatography.55 To en-
rich Loxoprofen racemate as a binary mixture, and to char-
acterize its enantiomer, the authors performed experiments
with various types of columns. When TBB column, CSP
based on the protein from buckwheat (Fagopyrum) was
used, the mixture of (1R,2S) and (1S,2S) forms was eluted
as a raffinate, while that of (1R,2R) and (1S,2R) forms was
discharged as an extract under linear adsorption isotherm
range. When the feed flow rates were 0.1 and 0.3 mL
min–1, the purities of the raffinate and extract were 98 %
and 95 %, resp. In this case, the productivity of raffinate was
7.81 g g–1 h–1 CSP, and that of the extract was 6.95 g g–1 h–1
CSP. These results enabled preparation of multigram quan-
tities of (1S,2S)-4, required for in vivo tests on anti-inflam-
matory activity.
3.2. Additional examples of SMB separation
of commercially important, biologically
active compounds and their intermediates
In this section are selected the most recent examples from
the scientific and patent literature on SMB separation of
commercially important racemates, either drugs or biologi-
cally active compounds of general interest, and their key in-
termediates.
Rolipram (5), 4-(3-(cyclopentyloxy)-4-methoxyphenyl)pyr-
rolidin-2-one. Rolipram (Adeo) is an antidepressant with
significant pharmacological properties. Although Rolipram
is often used as a racemate in biological experiments, the
biological activity of the enantiomers proved widely di-
vergent and R-Rolipram tends to be more potent than
S-Rolipram.56,57 Therefore, it is desirable to use this com-
pound routinely as a single enantiomer for both in vitro and
in vivo studies.58,59
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Separation of the intermediary N-Boc-Rolipram racemate
has been completed on cellulose tris-(3,5-dimethylphe-
nylcarbamate) CSP coated on silica by SMB chromatogra-
phy.60 The experiments were carried out under diluted
conditions. The operating condition was defined using the
point chosen in the triangle-shaped diagram, as shown in
Table 1. Chosen were a switch time (t*) of 20 min, and a
feed mass concentration of 2.5 g L–1 (linear condition).
Henry’s constants were determined and the system re-
vealed selectivity close to 1.26.
T a b l e 1 – Operating conditions based on the triangle ap-
proach (switch time of 20 min and feed mass concentration of 2.5 g
L–1)60
T a b l i c a 1 – Radni uvjeti zasnovani na pristupu trokutom (vri-
jeme okreta 20 min i masena koncentracija dotoka 2,5 g L–1)60
Flow rate ratios of each
section of SMB unit
Omjeri protoka svake
sekcije jedinice SMB
Fluid flow rates of the inlet and outlet
streams of SMB unit (mL min–1)
Protoci fluida ulaznih i izlaznih struja
jedinice SMB (mL min–1)
y1 y2 y3 y4 Din Dout F Ex Raf
3.25 2.56 2.64 1.40 1.06 0.64 0.10 0.24 0.28
Purity, the enantiomeric excess of the extract and raffinate,
and other performance parameters of the studied system
were determined, Table 2. Results showed reasonable per-
formance of the SMB unit to separate the N-Boc-Rolipram
enantiomers.
T a b l e 2 – Analyses of purity and enantiomeric excess (e.e.)
of the extract and raffinate streams60
T a b l i c a 2 – Analiza èistoæe i enantiomernog viška (e.e.) u
struji ekstrakta i rafinata60
Cycle
Ciklus
Analysis
of the raffinate stream
Analiza struje rafinata
Analysis
of the extract stream
Analiza struje ekstrakta
purity (%)
èistoæa (%) e.e. (%)
purity (%)
èistoæa (%) e.e. (%)
1 - - - -
2 - - 58.72 17.44
3 - - 76.87 53.74
4 70.45 40.90 77.30 54.60
5 89.91 79.82 76.77 53.54
6 91.43 82.86 75.75 51.50
Propranolol (6), 1-(-naphthyloxy)-2-hydroxy-3-dimethyl-
aminopropane. Resolution of Propranolol hydrochloride
(Inderal) was studied in self-packed columns of perphenyl
carbamoylated -cyclodextrin (-CD).61
Both bed void volume and linear equilibrium constants
were evaluated from linear elution chromatograms by mo-
ment analysis. A modified H-root method was used to de-
termine competitive Langmuir isotherm of Propranolol
hydrochloride in the nonlinear region. Continuous separa-
tion of the target enantiomer from its racemic mixture was
studied by SMB in both linear and nonlinear region. De-
sired S-Propranolol hydrochloride was produced in the
raffinate at a high purity. SMB productivity was further in-
creased at the expense of decreasing product purity. The
obtained solution was further purified by the crystallization
process.
Bupivacaine (7), 1-butyl-N-(2,6-dimethylphenyl)pypecolin-
amide. Bupivacaine (Marcaine) belongs to long-lasting local
anesthetics, drugs that block nerve conduction when they
are applied locally to nerve tissue at appropriate concentra-
tions.62 The compound is historically marketed as a race-
mate but clinical studies have shown that S-enantiomer
(levobupivacaine) is less cardiotoxic and also exhibits a
weaker CNS toxicity in men, making its application signifi-
cantly safer than that of racemate.63 Although the racemate
is used more often in medicine,64 the S-enantiomer (mar-
keted under the trade name Chirocaine) is recommended
in place of bupivacaine.65
Utilizing SMB, the conditions for separation of Bupivacaine
enantiomers were determined by the triangle theory and
simulations using the gPROMS software and the Aspen
Chromat. package.66 The SMB model in this study assumed
an axial dispersion flow for the liquid phase, and the intra-
particle mass transfer was described in terms of a simple lin-
ear driving force (LDF) approximation. The parameters a
and b of the Langmuir adsorption isotherm (LAI) were de-
termined using a dynamic method. In the optimal condi-
tion, the calculated concentrations were confirmed by the
V. ŠUNJIÆ et al.: Recent Achievements in Simulated Moving Bed, Kem. Ind. 59 (6) 283–294 (2010) 291
experimental results. Values projected by the gPROMS soft-
ware more closely matched experimental values than those
projected by the Aspen Chromat. package.
Zopiclone (8), N,N-6-trimethyl-2-(4-methylphenyl)imida-
zo[1,2-a]pyridine-3-acetamide, hemitartarate. Zopiclone
(Sepracor®), a cyclopyrrolone sharing activity with benzo-
diazepines in the CNS, is a short-acting sedative being de-
veloped by Sepracorfor for potential treatment of sleeping
disorders. Sepracor was granted US-05786357 in August
1998 covering methods and compositions of S-zopiclone in
the treatment of sleeping disorders. In August 2000, Merrill
Lynch predicted S-zopiclone sales of US $30 million in
2002, rising to US $150 million in 2004.67 Racemic form of
Zopiclone (Zolpidem) or salt thereof are presently used for
the treatment of anxiety or insomnia.68 In view of favorable
pharmacodynamic properties of S-enantiomer, an efficient
resolution method was desirable.
To this end, a SMB process for enantiomeric separation of
zopiclone was claimed by the group from Merck Develop-
ment Center Ltd, UK.69 The authors claimed stationary
phase used in the SMB process that comprised amylose or
cellulose derivatives of tris-(3,5-dimethylphenyl carbama-
te), or an amylose derivatives of tris-(p-methylbenzyl carba-
mate). The process can be carried out on industrial scale,
and provides S-Zopiclone of >99 % e.e., and a pharmaceu-
tically acceptable salt thereof.
Omeprazol (9), 5-methoxy-2-(4-methoxy-3,5-dimethyl-2-
-pyridyl)methylsulfinyl-1H-benzimidazole. Omeprazole (Pri-
losec) is a proton pump inhibitor drug in widespread use for
the reduction of gastric acid secretion. It is effective in the
treatment of gastro-esophageal reflux disease, gastric ulcer
or, together with antibiotic therapy, in the eradication of
Helicobacter pylori infections.70
This compound possess a stereogenic center at the sulphur
atom, and due its configurational stability is amenable to
chromatographic enantioseparation and application in the
enantiomerically pure form. The application of the pure
S-enantiomer (Nexium®) avoids undesired metabolic path-
way, and it is reported that it may lead to overall higher suc-
cess rates in the treatment of various acid secretion related
diseases.71
Favorable pharmacological properties of S-Omeprazole
prompted various teams in industry72,73 and academy74 to
develop chromatographic methods for the large-scale sepa-
ration of racemate. Thus, a Chinese team has claimed SMB
system with chiral fixed phase of cellulose tri-phenylcar-
bamate and eluens (desorbent) consisting of a mixture of
ethanol, n-hexane and diethylamine. Racemic mixture of
Omeprazole is separated to obtain high purity S-Omepra-
zole. The separation process is a continuous process, has
high automation, high production efficiency, low solvent
consumption and no toxic solvent.
Nadolol (10), (2R,3S)-5-{(2R-3-(tert-butylamino)-2-hydroxy-
propyloxy}-1,2,3,4-tetrahydronaphthalene-2,3-diol. Nado-
lol (Corgard, Corzide) is a well known -blocker drug used
in the management of hypertension and angina pecto-
ris.75,76 It has also been proved in pharmacologic treatment
of portal hypertension in the prevention of community-
-acquired spontaneous bacterial peritonitis.77
It has three chiral centers, i.e. eight (23) stereoisomers. It is
currently marketed as an equal mixture of 4 stereoisomers,
two diastereomeric racemates with cis-hydoxy groups in
the cyclohexane unit.
In the preliminary experiments for SMB separation, resolu-
tion of 3 of the 4 racemic mixtures of Nadolol was obtained
by HPLC, with a complete separation of the most active
enantiomer (R,S,R)-Nadolol, on a column packed with per-
phenyl carbamoylated -cyclodextrin (-CD) immobilized
onto silica gel. Continuous separation of enantiomer (R,S,R)-
-Nadolol from its racemate, in both 2-raffinate and 2-
-extract configuration of 5-zone SMB was achieved.78 Ex-
perimental setup was applied to both configurations by
modifying SMB controlling program accordingly. Separa-
tion performances of the 5-zone SMB were investigated for
both 2-raffinate and 2-extract configurations and the same
safety factors were applied to systematically investigate the
effect of y3 – y2 (or y4 – y3) on the separation performance.
The desired enantiomer of Nadolol was obtained with a
high purity and yield in 2-raffinate configuration.
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4. Conclusion
Modeling of continuous chromatographic separation, ba-
sed on experimental chromatographic parameters, has en-
abled development of SMB technology. Part I of this review
presents the elementary principles of SMB process model-
ing, and recent applications of SMB in separation of com-
mercially important, optically pure compounds. These tar-
get compounds are mostly drugs in development or in
therapeutic use, and therefore represent huge potential or
already achieved market value. Due to the importance of
these compounds, some details of their biological and
medical profile are given, as well as characteristic parame-
ters of the SMB separation process.
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List of symbols
Popis simbola
A – cross sectional area, mm2
– presjek, mm2
c – concentration of solute in fluid, mol L–1
– koncentracija tvari u fluidu, mol L–1
D – dispersion coefficient, m2 s–1
– disperzni koeficijent, m2 s–1
di – inner diameter of column, mm
– unutarnji promjer kolone, mm
e.e. – enantiometric excess, %
– enantiomerni višak, %
H – Henry constant
– Henryjeva konstanta
K – chromatographic constant
– kromatografska konstanta
k – mass transfer coefficient, m s–1
– koeficijent prijenosa mase, m s–1
n – concentration of solute in solid phases, mol L–1
– koncentracija otopljene tvari u èvrstoj fazi, mol L–1
n* – solid phase concentration in equilibrium with fluid
phase, mol L–1
– koncentracija èvrste faze u ravnoteÞi s tekuæom fazom,
mol L–1
P – productivity, me.e t
–1, g g–1h–1
– produktivnost, me.e t
–1, g g–1h–1
Q – volume flow rate, mL min–1
– obujamski protok, mL min–1
t – time, min, h
– vrijeme, min, h
V – volume, mL, L
– obujam, mL, L
z – axial coordinate, m
– aksijalna koordinata, m
 – chromatographic enantioseparation factor
– kromatografski enantioseparacijski faktor
e – void fraction of the column
– nepopunjen udjel u koloni
e* – overall void volume
– sveukupan nepopunjen obujam
y – volume ratio, mL min–1
– obujamski omjer, mL min–1
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SAÝETAK
Novija dostignuæa tehnologije simuliranog pokretnog leÞaja. I. Dio.
V. Šunjiæ, a D. Franiæ, a D. Kontrecb i M. Rojeb
Tehnologija simuliranog pokretnog leÞaja poznata je više od pola stoljeæa na podruèju kontinuira-
ne kromatografske separacije binarnih smjesa. Otkrivena i razvijena u petrokemijskoj i industriji
šeæera, ova tehnologija je prepoznata od strane organskih kemièara u farmaceutskoj industriji kao
moæno oruðe za separaciju racemiènih smjesa. Niz godina razvijana je kao standardna laborato-
rijska metoda, zatim kao postupak za pilotna postrojenja, i konaèno kao industrijska metoda za
dobivanje kiralnih spojeva u optièki èistom obliku. Konaèni produkti ove tehnologije su enantio-
merno èisti lijekovi te drugi biološki aktivni spojevi i njihovi intermedijari. U prvom dijelu ovog
pregleda prikazani su osnovni principi i odabrani primjeri nedavne primjene tehnologije SMB.
a Chirallica d. o. o., Bijenièka cesta 54, Prispjelo 28. rujna 2009.
a 10002 Zagreb, Hrvatska Prihvaæeno 22. travnja 2010.
b Institut Ruðer Boškoviæ, Bijenièka cesta 54,
a 10002 Zagreb, Hrvatska
